Table 1.
Multivariable Cox regression analysis of DDX21 and CEP55 as factors prognostic for outcome in 493 patients a .
| Factors | Overall survival | Event‐free survival | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| High DDX21 expression (median as the cutoff) | 1.99 (1.18–3.36) | 0.0098 | 1.69 (1.20–2.38) | 0.0029 |
| MYCN amplification | 3.07 (2.00–4.72) | < 0.0001 | 1.54 (1.09–2.19) | 0.0145 |
| Age > 18 months | 2.38 (1.55–3.66) | < 0.0001 | 1.78 (1.29–2.46) | < 0.0001 |
| Stages 3 and 4 b | 5.98 (2.86–12.48) | < 0.0001 | 2.81 (1.89–4.19) | 0.0004 |
| High DDX21 expression (upper quartile as the cutoff) | 1.94 (1.26–2.97) | 0.0025 | 1.52 (1.08–2.13) | 0.0163 |
| MYCN amplification | 3.02 (1.95–4.67) | < 0.0001 | 1.56 (1.09–2.25) | 0.0160 |
| Age > 18 months | 2.53 (1.65–3.89) | < 0.0001 | 1.82 (1.32–2.51) | 0.0003 |
| Stages 3 and 4 b | 5.93 (2.84–12.38) | < 0.0001 | 2.89 (1.94–4.31) | < 0.0001 |
| High CEP55 expression (median as the cutoff) | 3.01 (1.69–5.35) | 0.0002 | 1.98 (1.39–2.83) | 0.0002 |
| MYCN amplification | 3.28 (2.19–4.91) | < 0.0001 | 1.64 (1.17–2.28) | 0.0038 |
| Age > 18 months | 2.19 (1.41–3.40) | 0.0005 | 1.75 (1.26–2.43) | 0.0009 |
| Stages 3 and 4 b | 4.94 (2.33–10.49) | < 0.0001 | 2.45 (1.62–3.72) | < 0.0001 |
| High CEP55 expression (upper quartile as the cutoff) | 2.53 (1.70–3.76) | < 0.0001 | 2.16 (1.58–2.96) | < 0.0001 |
| MYCN amplification | 3.68 (2.46–5.51) | < 0.0001 | 1.64 (1.17–2.28) | 0.0036 |
| Age > 18 months | 2.58 (1.68–3.98) | < 0.0001 | 1.83 (1.32–2.52) | 0.0003 |
| Stages 3 and 4 b | 5.35 (2.55–11.21) | < 0.0001 | 2.54 (1.69–3.82) | < 0.0001 |
The level of DDX21 or CEP55 expression was considered high or low in relation to the median or upper quartile level of expression in tumors of the RNA sequencing gene expression‐patient prognosis SEQC‐RPM‐seqcnb1 dataset. HRs were calculated as the antilogs of the regression coefficients in the proportional hazard regression. Multivariable Cox regression analysis was carried out following the inclusion of the four factors listed above into the Cox regression model, and P value was obtained from two‐sided log‐rank test.
Tumor stage was categorized as favorable (International Neuroblastoma Staging System stages 1, 2 and 4S) or unfavorable (International Neuroblastoma Staging System stages 3 and 4).